CLAIMS

1. Use of an antibody for the manufacture of a medicament for treating rheumatoid arthritis in a subject previously treated by administration of methotrexate, leflunomide, sulfasalazine and/or hydroxychloroquine, wherein the antibody comprises the heavy chain variable region of sequence SEQ ID NO:2 and the light chain variable region of sequence SEQ ID NO:3, wherein the antibody is to be administered to the subject at between 100 mg and 200 mg per two weeks~~, and wherein said subject was previously treated for rheumatoid arthritis by administration of a biologic TNF-α antagonist.~~

2. The use of claim 1, wherein the subject was previously ineffectively treated for rheumatoid arthritis by administration of methotrexate, leflunomide, sulfasalazine and/or hydroxychloroquine.

3. The use of claim 2, wherein methotrexate, leflunomide, sulfasalazine and/or hydroxychloroquine is to be administered together with the antibody.

4. The use of claim 3, wherein the antibody and methotrexate are to be administered together.

5. The use of claim 4, wherein methotrexate is to be administered between 6 to 25 mg per week.

6. The use of claim 1, wherein the antibody is to be administered at 150 mg per two weeks.

7. The use of claim 1, wherein the antibody is to be administered at 200 mg per two weeks.

8. The use of any of claims 1-7, wherein the subject achieves a 20% improvement in the American College of Rheumatology core set disease index after 12 weeks of treatment.